Username Password
S&P 500: 1,348.81 Change: +0.37%

ACHILLION PHARMACEUTICALS INC (ACHN)

Overview
Price 10.38
Price Change Today -$1.20 (-10.37%)
P&P rating Rating: 0
Zacks Rank 3 - HOLD
Open Price $10.76
Previous Close $11.57
Daily Range $9.52 - $10.77
52-Week Range $3.81 - $12.95
Volume 4,518,829
chart
ACHILLION PHARMACEUTICALS, INC. is an innovative pharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. The company's proven discovery and development teams have advanced multiple product candidates with novel mechanisms of action. Achillion is focused on solutions for the most challenging problems in infectious disease -- HIV, hepatitis and resistant bacterial infections. Achillion sees significant competitive advantages in developing anti-infective drugs compared to developing drugs in other therapeutic areas. The emergence of drug resistance seen with current antiviral and antibacterial therapies creates a continuing need for new drugs, providing a large and growing potential business opportunity. In addition, development cycle times tend to be somewhat shorter in infectious disease than other therapeutic areas, and early drug development results tend to be more predictive of longer term results.
Other Resources for ACHN
zacks.com
Commentary
Zacks Blog: Company News for January 25, 2012
January 25, 2012
Zacks Blog: Zacks.com featured expert Kevin Matras highlights: Ulta Salon, Cosmetics & Fragrance, Inc., Hexcel Corp., On Assignment, Inc., Advance America, Cash Advance Centers, Inc. and Achillion Pharmaceuticals, Inc.
December 13, 2011
Zacks Blog: Company News for September 9, 2011
September 9, 2011
ACHILLION PHARMACEUTICALS, INC. is an innovative pharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. The company's proven discovery and development teams have advanced multiple product candidates with novel mechanisms of action. Achillion is focused on solutions for the most challenging problems in infectious disease -- HIV, hepatitis and resistant bacterial infections. Achillion sees significant competitive advantages in developing anti-infective drugs compared to developing drugs in other therapeutic areas. The emergence of drug resistance seen with current antiviral and antibacterial therapies creates a continuing need for new drugs, providing a large and growing potential business opportunity. In addition, development cycle times tend to be somewhat shorter in infectious disease than other therapeutic areas, and early drug development results tend to be more predictive of longer term results.
 
Brokerage Analyst Recommendations
14 Brokerage Firms Covering ACHN
 
  
Strong Buy
12
Buy
0
Hold
2
Sell
0
Strong Sell
0
Average Broker Recommendation (ABR): 1.29
 
ACHN Ratings:BUY  SELL  HOLD
ACHN Consensus Forecasts
Rate this Stock!
You haven't rated this stock yet!

What The Community Thinks

Total Players

1 Buy
0 Sell
 
Top Buy Analysis
BUY: ACHN Rating: 0
Company: ACHILLION PHARMACEUTICALS INC.
Points: 36.39
Start Price: $7.26
Start Date: 06/22/2011 2:24 PM
wallstreeter
wallstreeter
P&P Score: 0.23
Recs:
Turning up from correction

Comments: 0 | Comment


Top Sell Analysis
No Sell Analysis. Be the First.
Blog Posts
No related Blog Posts.
Commentary
BUY: ACHILLION PHARMACEUTICALS INC. (ACHN)
Start Price: $7.26
Points: +36.39
Created: 06/22/2011
Turning up from correction

Comments: 0 | Comment

Recs:
 
Picks
Username P&P Score Call Time Frame Start Date Start Price Today (change) Stock Gain S&P Gain Points Analysis
wallstreeter 0.23 BUY Six Months to a Year 06/22/2011 $7.26 $10.25
(-11.56%)
+41.18% +4.79% +36.39 view
Sponsored Links